Racemic (R,S)-propranolol Versus Half-dosed Optically Pure (S)-propranolol in Humans at Steady State: Hemodynamic Effects, Plasma Concentrations, and Influence on Thyroid Hormone Levels
Overview
Affiliations
In a randomized, double-blind, crossover study in 10 healthy volunteers the hemodynamic effects, drug plasma concentrations, and thyroid hormone profiles were compared after oral administration for 1 week of 40 mg t.i.d. racemic (R,S)-propranolol versus 20 mg t.i.d. optically pure (S)-propranolol. During exercise, both substances decreased heart rate (-14%, p less than 0.01), as well as the overall rate pressure product (-19%, p less than 0.01) to the same extent, indicating similar beta-blocking effects. After oral application of (R,S)-propranolol the maximal plasma concentration (Cmax) and the area under the plasma concentration-time curve (AUC) of (S)-propranolol were higher than those of (R)-propranolol (eudismic ratios (S)- over (R)-propranolol Cmax, 1.36 [p less than 0.01] and AUC, 1.42 [p less than 0.01]) despite dose-equivalence of both enantiomers in the administered racemic (R,S)-propranolol preparation indicating different pharmacokinetic properties. Mean values of Cmax and the AUC of (S)-propranolol did not differ significantly after 1 week of oral administration of 40 mg (R,S)-propranolol and 20 mg (S)-propranolol t.i.d., respectively. The ratio of triiodothyronine to thyroxine was decreased by (R,S)-propranolol (-25%, p less than 0.01) but not by (S)-propranolol, suggesting that only the (R)-enantiomer inhibits the conversion of thyroxine to triiodothyronine. Thus, half-dosed optically pure (S)-propranolol is an equally effective beta-adrenergic receptor antagonist compared with currently used racemic (R,S)-propranolol. By contrast, the conversion of thyroxine to triiodothyronine is inhibited by (R)-propranolol only.(ABSTRACT TRUNCATED AT 250 WORDS)
Holm A, Tan J, Borgelt L, Mulliken J, Bischoff J J Vasc Anom (Phila). 2025; 5(3).
PMID: 39866206 PMC: 11759103. DOI: 10.1097/jova.0000000000000096.
Chirality of New Drug Approvals (2013-2022): Trends and Perspectives.
McVicker R, OBoyle N J Med Chem. 2024; 67(4):2305-2320.
PMID: 38344815 PMC: 10895675. DOI: 10.1021/acs.jmedchem.3c02239.
Mechanoenzymology in the Kinetic Resolution of β-Blockers: Propranolol as a Case Study.
Gamboa-Velazquez G, Juaristi E ACS Org Inorg Au. 2023; 2(4):343-350.
PMID: 36855594 PMC: 9955203. DOI: 10.1021/acsorginorgau.1c00049.
Seebauer C, Graus M, Huang L, McCann A, Wylie-Sears J, Fontaine F J Clin Invest. 2021; 132(3).
PMID: 34874911 PMC: 8803322. DOI: 10.1172/JCI151109.
Understanding the pharmacokinetics of reversible metabolism.
Cho S, Yoon Y Transl Clin Pharmacol. 2020; 27(2):52-58.
PMID: 32055581 PMC: 6989244. DOI: 10.12793/tcp.2019.27.2.52.